Parvus enters agreement to advance PVT-201 for primary biliary cholangitis Dec. 1, 2021 Parvus Therapeutics has announced an agreement with National Resilience for the tech transfer, scale-up and GMP manufacturing of PVT-201, Parvus' lead Navacim drug candidate being developed to treat primary biliary cholangitis.Read More
XIAP deficiency is associated with susceptibility to microbial triggers of intestinal inflammation Nov. 25, 2021
RSS